Related Experiment Video
Updated: Sep 14, 2025
Using Lipid Nanoparticles for the Delivery of Chemically Modified mRNA into Mammalian Cells
Published on: June 10, 2022
Exploring the future of mRNA delivery: Beyond lipid nanoparticles
Aljoscha Gabelmann1, Achim Biesel1, Brigitta Loretz2
1Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz-Centre for Infection Research (HZI), Campus E8.1, 66123, Saarbrücken, Germany; Department of Pharmacy and Pharma Science Hub (PSH), Saarland University, 66123, Saarbrücken, Germany.
Lipid nanoparticles (LNPs) are key for mRNA delivery, but have limitations. This review explores solutions like improved mRNA stability, novel materials, and advanced delivery devices for next-generation mRNA therapeutics.
Area of Science:
- Biotechnology
- Nanomedicine
- Pharmaceutical Sciences
Background:
- Lipid nanoparticles (LNPs) are the established standard for messenger RNA (mRNA) delivery, crucial for developing mRNA vaccines during the COVID-19 pandemic.
- Despite their success, current LNP formulations exhibit inherent limitations impacting their efficacy and safety.
- Addressing these limitations is critical for advancing mRNA technology beyond vaccines.
Purpose of the Study:
- To critically evaluate the limitations of current lipid nanoparticle (LNP) technology for mRNA delivery.
- To explore emerging strategies and novel materials for enhancing mRNA stability and therapeutic efficacy.
- To discuss innovative delivery systems and manufacturing advancements for next-generation mRNA formulations.
Main Methods:
- Review of fundamental research and technological innovations in LNP formulation and mRNA delivery.
- Analysis of strategies for improving mRNA stability, including lyophilization techniques.
- Investigation of novel materials (e.g., poly (beta-amino esters), alternative lipids) and hybrid nanoparticle systems.
- Comparison of passive and active targeting strategies with novel medical devices (inhalers, microneedles).
Main Results:
- Identified key limitations in current LNP technology requiring further optimization.
- Highlighted strategies for enhancing mRNA stability and translational efficiency.
- Introduced novel materials and hybrid systems for improved delivery, reduced toxicity, and targeted delivery.
- Evaluated advanced delivery devices and manufacturing technologies for personalized medicine.
Conclusions:
- Significant advancements in LNP technology offer solutions to current limitations, paving the way for improved mRNA therapeutics.
- Novel materials, formulation stabilization, and targeted delivery systems are crucial for next-generation mRNA applications.
- Manufacturing, analytical, regulatory, and IP considerations are vital for the successful commercialization of advanced mRNA formulations.
